Cancer chemoprevention as a concept and research methodology that examines inhibition of human carcinogenesis by nutritional, phytochemical, and other pharmacological substances dates to at least the early 1980s ( 1 , 2 ). At that time, a flurry of chemoprevention trials was launched predicated on epidemiological observations regarding potential protective roles for a wide range of foods and nutrients, including retinoids, beta carotene, calcium, and lower dietary fat in several cancers, and on basic research that provided both corroboration of the hypotheses through tumor inhibition in experimental models and evidence relevant to the responsible biological mechanisms. However, only a few of the randomized controlled studies, or RCT's, have demonstrated the hoped-for reductions -or even unanticipated benefits -in incidence or recurrence of neoplasia from nutrient supplementation or dietary modification. For example, the Nutritional Prevention of Cancer Study, which aimed to prevent nonmelanoma skin cancers with selenized yeast, failed to do so, but unexpected yet statistically significant reductions in prostate, lung, and colorectal cancers were observed ( 3 ). Similarly, the Nutritional Intervention Trial targeted a high esophageal cancer incidence area and found a 21% reduction in gastric (but not esophageal) cancer mortality in response to a selenium, beta carotene, and vitamin E combination ( 4 ). In the Calcium Polyp Prevention Study, daily supplementation with calcium carbonate did lead to a 15% reduction in colorectal adenomatous polyp recurrence ( 5 ). The majority of similar cancer trials demonstrated no chemopreventive efficacy for their primary neoplastic endpoints [eg, ( 6 -9 )], and in some there was evidence of unexpected harmful effects, such as an increased number of lung cancers in those receiving beta carotene in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study ( 10 , 11 ) and Beta-Carotene and Retinol Efficacy Trial (CARET) ( 12 , 13 ), and an increased number of colorectal neoplasias in participants receiving folic acid in the Aspirin/ Folate Polyp Prevention Study ( 14 ). Other nonsupplementation trials of dietary modification including two that assessed the effect of lower fat intake yielded statistically null results for their primary hypotheses ( 15 , 16 ), although the latter study showed a small breast cancer incidence reduction.
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The fi ndings of Lin et al. ( 17 ) in this issue of the Journal fall into the well-populated category of null trials. Using a factorial design, the Women's Antioxidant Cardiovascular Study, or WACS, tested supplementation for 8 -10 years with beta carotene (50 mg daily), vitamin C (as ascorbic acid, 500 mg daily), and vitamin E (as RRR-alpha-tocopherol, 600 IU every other day) in more than 7600 women who at study entry were at least 40 years old and at elevated risk of cardiovascular disease. Based on 624 cancer diagnoses (41% of which were breast cancers) and 176 cancer deaths, the investigators observed relative risks (RRs) for the beta carotene, vitamin C and vitamin E trial arms of 1.00, 1.11, and 0.93, respectively, for overall cancer incidence, and 0.84, 1.28, and 0.87, respectively, for relative mortality. The investigators concluded that the vitamins had no effect, singly or in combination. Duration of active supplementation within the range studied, compliance, and "drop-in" use of extrastudy supplements did not appear to account for the fi ndings. By contrast, the "lack of complete follow-up" alluded to by the investigators as a methodological limitation [presumably the 93% follow-up completeness through January 31, 2005 ( 18 ) , and/or exclusion of approximately 40 unconfi rmed cases] or the high cardiovascular disease (CVD) risk of the study population which might overshadow other health benefi ts may have contributed to the lack of effi cacy for the cancer endpoints. Neither the antioxidants nor the fourth intervention added later -a combination of folic acid and vitamins B 6 and B 12 -had any statistically signifi cant effects in terms of cardiovascular disease endpoints ( 18 , 19 ) . Their just-reported fi ndings for folic acid -B vitamins and cancer were that overall rates and breast cancer rates were comparable in the active and placebo arms ( 20 ) . Thus, taken as a whole, WACS provides little or no evidence that such vitamin supplementation as tested offers any measurable preventive impact on cancer in women.
Despite the trial's conclusion that there were no overall benefi ts for primary cancer prevention, two of the specifi c fi ndings reported by Lin et al. ( 17 ) deserve additional mention because they corroborate previous trial results and demonstrate the potential for site-specifi c effi cacy. The fi rst is the possible effect of vitamin E supplementation in preventing colorectal cancer (RR = 0.63), similar to what was observed in the ATBC Study ( 20 ) and in a pooled analysis of serum tocopherol levels in cohort studies ( 21 ) . The second is the elevated lung cancer risk in the beta carotene arm, along with modest excess overall cancer risk in smokers and heavier drinkers. The suggested harmful effects from vitamin C for lung and pancreatic cancers, with the former effect achieving statistical signifi cance, are also noteworthy and raise questions concerning the chemopreventive potential of ascorbic acid. All these observations, based on the randomized design, represent value-added data that will contribute to a better understanding of cancer etiology and prevention and the appropriate role of these micronutrient supplements.
Nutritional intervention trials inevitably test multiple biological effects that can and should be expected even with single-agent supplements such as those used in WACS. Functionally diverse putative cancer preventive mechanisms have been demonstrated for vitamins C and E, beta carotene, and many other nutrients that have been tested in tumorigenesis and cell culture experiments. These mechanisms include inhibition of, or interference with, oxidative damage and free radical formation, cell proliferation, retinoic acid receptor signaling, angiogenesis, nitrosamine formation, and infl ammation, as well as enhancement of apoptosis, cellular differentiation, and immune function ( 22 ) . Nutritional supplements also modulate integral cellular detoxifi cation and other metabolic pathways, notably cytochrome p450 enzymes (e.g., CYP 1A1), that have extensive and diverse effects on metabolism [see, for example, ( 23 )]. This could be one explanation for some of the fi ndings of recent meta-analyses suggesting adverse effects in trials where dosages and the role of high-risk populations have been considered [eg, ( 24 , 25 ) ]. Conversely, because cell culture experiments can demonstrate benefi cial effects for thousands of compounds on myriad molecular targets ( 26 ) they should be followed by careful examination of safety clinical and observational data before selection of interventional agents, dosages, and target populations for future trials.
WACS is but the most recently reported example of an informative, effi cient, "multitasked" prevention study. Controlled trials allow for the simultaneous examination of primary and multiple secondary endpoints and thus help the research community, public health and medical practitioners, and the public gain a more comprehensive understanding of cancer preventative strategies that might be considered, including possible modifi cations of prevalent lifestyle behaviors such as vitamin supplement use in the United States ( 27 ) . These RCTs are an integral and important component of nutritional epidemiological cancer research programs that test mature hypotheses in the appropriate populations. The conduct of these trials has depended on experimental, dietary, and serologic studies that allowed for rational selection of candidate micronutrients that could be ethically and safely tested in controlled settings. Consideration of supplementation dosages should be in line with observational data where evidence based on middle-level or higher (but physiological and not pharmacological) intakes suggests benefi t. Vitamin E may be an example of this with WACS and many of the trials discussed here opting for 300 -400 IU of alpha-tocopherol per day in the face of the ATBC Study's benefi cial fi ndings for prostate cancer (and possibly colorectal and lung cancers) based on a 50-IU dose. Selection of study populations should also consider the possibility that persons of low or defi cient nutritional status might be most susceptible to intervention effi cacy [eg, ( 4 , 29 ) ].
The recent announcement of early termination of the Selenium and Vitamin E Cancer Prevention Trial's (SELECT) interventions because of lack of effi cacy and observation of possible adverse events (ie, small and not statistically signifi cant increases in type 2 diabetes in those receiving selenium alone and in prostate cancer incidence in the vitamin E (alone) group) should serve as a reminder that the unexpected can happen in these well-designed trials (30) . Large controlled studies are perhaps more likely to reveal unanticipated outcomes owing to at least two factors. One is the intense balancing that randomization imposes such that "confounding" and case -control differences in highly correlated lifestyle characteristics and risk factors play no role in an intervention outcome in a large RCT (although effect modifi cation of effi cacy can and has occurred). The other is the highly specifi c "exposure" represented by the intervention(s) -not a questionnaire estimation of a self-reported nutrient intake or a one-time blood sampling. Careful, comprehensive surveillance for a wide range of potential clinical outcomes and unknown adverse effects required for efficacy and safety monitoring in trials also contributes to multifaceted and unanticipated outcomes.
Progress in the fi eld of cancer prevention, as in most scientifi c pursuits, can vary from slow, incremental accumulation and synthesis of new fi ndings relevant to a range of hypotheses, to quantum advances from much anticipated corroboration or refutation of hypotheses and pure surprises. It is easy to view unexpected RCT outcomes as failures or proof of an overly simplifi ed or overly sold concept, and obviously, the most satisfying trials are those that deliver the goods; that is, they show their anticipated cancer prevention effects. Null trials or those with unexpected outcomes should not, however, be viewed as failures; they have and will continue to shed light on the causes of cancer and help us discover the means for its prevention.
